CTRP1、CTRP3水平变化在评估阿替普酶静脉溶栓后序贯替罗非班治疗超急性期缺血性脑卒中的临床价值  

Changes in CTRP1 and CTRP3 levels in evaluating the clinical value of sequential tirofiban treatment for hyperacute ischemic stroke after intravenous thrombolysis with alteplase

作　　者：曾庆银 杜娟 Zeng Qing-yin;Du Juan(Department of Neurology,Dengzhou People's Hospital,Dengzhou 474150,Henan,China)

机构地区：[1]邓州市人民医院神经内科,河南邓州474150

出　　处：《四川生理科学杂志》2025年第4期871-874,共4页

摘　　要：目的:探讨细胞分泌蛋白1(C-type lectin repeat protein-1,CTRP1)、细胞分泌蛋白3(C-type lectin repeat protein-3,CTRP3)水平变化在评估阿替普酶+替罗非班治疗超急性期缺血性脑卒中的临床价值。方法:研究本院2021年06月至2024年01月纳入的92例超急性期缺血性脑卒中患者随机分为观察组、对照组各46例。对照组实施阿替普酶静脉溶栓治疗,观察组给予阿替普酶静脉溶栓后序贯替罗非班治疗。比较两组治疗效果,Barthel评分和美国卫生部卒中量表(National Institute of Health Stroke Scale Score,NIHSS)评分,CTRP1和CTRP3水平,血脂水平,不良事件发生率情况。结果:治疗总有效率观察组高于对照组(P<0.05)。治疗后两组Barthel评分和NIHSS评分均改善,与对照组相比观察组更优(P<0.05)。治疗后12 h、24 h两组CTRP1和CTRP3水平均依次降低,与对照组相比,观察组CTRP1和CTRP3水平更低,(P<0.05)。治疗后两组血脂水平均降低,与对照组相比,观察组各血脂水平更低(P<0.05)。观察组总不良事件发生率低于对照组(P<0.05)。结论:阿替普酶+替罗非班在超急性期缺血性脑卒中患者治疗中可有效改善患者的日常生活能力及神经功能缺损,降低患者的血脂水平,CTRP1、CTRP3水平逐渐降低,不良事件发生率较低,临床疗效显著。Objective:Exploring the clinical value of evaluating the changes in levels of C-type lectin repeat protein-1(CTRP1)and C-type lectin repeat protein-3(CTRP3)in the treatment of hyperacute ischemic stroke with alteplase and tirofiban.Method:A total of 92 patients with hyperacute ischemic stroke admitted to our hospital from June 2021 to January 2024 were randomly divided into a control group and an observation group,with 46 patients in each group.The control group received intravenous thrombolysis with alteplase,while the observation group received sequential treatment with tirofiban after intravenous thrombolysis with alteplase.The treatment outcomes of two groups were compared,including Barthel score and National Institute of Health Stroke Scale Score(NIHSS)score,CTRP1 and CTRP3 levels,blood lipid levels,and incidence of adverse events.Result:The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,both groups showed improvement in Barthel and NIHSS scores,and both scores in the observation group were better than those in the control group(P<0.05).After 12 hours and 24 hours of treatment,the levels of CTRP1 and CTRP3 in both groups decreased sequentially.Compared with the control group,the observation group had lower levels of CTRP1 and CTRP3(P<0.05).After treatment,the blood lipid levels in both groups decreased.Compared with the control group,the observation group had lower blood lipid levels in all groups(P<0.05).The incidence of total adverse events in the observation group was lower than that in the control group(P<0.05).Conclusion:The combination of alteplase and tirofiban can effectively improve the daily living ability and neurological deficits of patients with hyperacute ischemic stroke,reduce their blood lipid levels,gradually decrease CTRP1 and CTRP3 levels,and reduce the incidence of adverse events.The clinical efficacy is significant.

关 键 词：CTRP1 CTRP3 阿替普酶 罗非班 缺血性脑卒中 

分 类 号：R743.3[医药卫生—神经病学与精神病学]